If you have been reading about Freeze-thaw and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-21. Numbers and descriptions here follow the published literature rather than marketing material.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or flake |
| Solubility class | Soluble in water and aqueous buffer | Also soluble in some polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Typical analytical method | LC-MS/MS | Reversed-phase separation with mass detection |
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
=== Long-term health effects === Some data about the health effects are still not available. The Indian Council of Medical Research (ICMR) was forbidden to publish health effect data until 1994. A total of 36 wards were marked by the authorities as being "gas affected", affecting a population of 520,000. Of these, 200,000 were below 15 years of age, and 3,000 were pregnant women. The official immediate death toll was 2,259, and in 1991, 3,928 deaths had been officially certified. The Sambhavna clinic "estimates 8,000 deaths during the first weeks, and another 8,000 since then". The government of Madhya Pradesh confirmed a total of 3,787 deaths related to the gas release. Later, the affected area was expanded to include 700,000 citizens. A government affidavit in 2006 stated the leak caused 558,125 injuries including 38,478 temporary partial injuries and approximately 3,900 severely and permanently disabling injuries. A cohort of 80,021 exposed people was registered, along with a control group, a cohort of 15,931 people from areas not exposed to MIC. Nearly every year since 1986, they have answered the same questionnaire. It shows excess mortality and morbidity in the exposed group. Bias and confounding factors cannot be excluded from the study. Because of migration and other factors, 75% of the cohort is lost, as the ones who move out are not followed. A number of clinical studies are performed. The quality varies, but the different reports support each other. Studied and reported long-term health effects are:
Over 2003–2013 for companies that approved 8–13 drugs, the cost per drug could rise to as high as $5.5 billion, due mainly to international geographic expansion for marketing and ongoing costs for Phase IV trials for continuous safety surveillance. Alternatives to conventional drug development have the objective for universities, governments, and the pharmaceutical industry to collaborate and optimize resources. An example of a collaborative drug development initiative is COVID Moonshot, an international open-science project started in March 2020 with the goal of developing an un-patented oral antiviral drug to treat SARS-CoV-2.
== D == DE(T)A – Dielectric thermal analysis dHvA – De Haas–van Alphen effect DIC – Differential interference contrast microscopy Dielectric spectroscopy DLS – Dynamic light scattering DLTS – Deep-level transient spectroscopy DMA – Dynamic mechanical analysis DPI – Dual polarisation interferometry DRS – Diffuse reflection spectroscopy DSC – Differential scanning calorimetry DTA – Differential thermal analysis DVS – Dynamic vapour sorption
Furthermore, leveraging strategic technical collaborations with global big tech — such as OpenAI, Microsoft, Google Cloud, AWS, Cohere, Anthropic, and Palantir—the company actively deploys enterprise operations encompassing generative AI, data analytics, AI agents, and cloud-based AX business. RX (Robotic Transformation): LG CNS accelerates robotic commercialization through its 'Full-Stack RX Services', which strategically combine industry-specific Robot Foundation Models (RFM), hardware, and platforms. Through 'PhysicalWorks', the first integrated robot learning and operations platform developed by a South Korean firm, the company trains robots for real-world industrial tasks, manages task and workflow allocation, and provides central orchestration to monitor and operate heterogeneous robot fleets under a single platform. The company is also collaborating with U.S.-based robotics innovators, such as 'Dexmate' and the robotic brain development firm 'Skild AI,' to co-develop advanced physical AI systems. Cloud & AI Data Centers: The company delivers cloud transformation consulting, integration, and Managed Service Provider (MSP) services, along with data center infrastructure development. LG CNS became the first South Korean firm to secure an overseas AI data center construction project, with plans to complete a hyper-scale AI data center in Jakarta, Indonesia, by the end of 2026. In the cloud infrastructure sector, it maintains strategic partnerships with AWS, Microsoft Azure, and Google Cloud.
Sources: en.wikipedia.org
=== Spinal nerves === A goal of spinal cord injury research is to promote neuroregeneration, reconnection of damaged neural circuits. The nerves in the spine are a tissue that requires a stem cell population to regenerate. In 2012, a Polish fireman Darek Fidyka, with paraplegia of the spinal cord, underwent a procedure, which involved extracting olfactory ensheathing cells (OECs) from Fidyka's olfactory bulbs, and injecting these stem cells, in vivo, into the site of the previous injury. Fidyka eventually gained feeling, movement and sensation in his limbs, especially on the side where the stem cells were injected; he also reported gaining sexual function. Fidyka can now drive and can now walk some distance aided by a frame. He is believed to be the first person in the world to recover sensory function from a complete severing of the spinal nerves.
Nicotinamide is recommended as a treatment for niacin deficiency because it can be administered in remedial amounts without causing the flushing, considered an adverse effect. In the past, the group was loosely referred to as vitamin B3 complex. Extra-terrestrial nicotinic acid and nicotinamide have been detected in carbonaceous chondrite meteorites and in sample-returns from the asteroids 162173 Ryugu and 101955 Bennu.
Pharmaceutical agents that will alter the natural history of disease progression by arresting joint structural change and ameliorating symptoms are termed as disease modifying therapy. Therapies under investigation include the following:
Sources: en.wikipedia.org
BASF announced that the transaction would allow the company to focus on its chemical and refinery catalysts business. Since 2016, BASF has partnered with a subsidiary of Xinjiang Zhongtai Group, a company sanctioned under the Uyghur Forced Labor Prevention Act, to operate a plant in Korla. In October 2017, BASF announced it would buy seed and herbicide businesses from Bayer for €5.9 billion ($7 billion), as part of Bayer's acquisition of Monsanto. The company announced the start of a US$10 billion investment project in the south-western Chinese city of Zhanjiang, in November 2019. The project was approved in 2022. This ″Verbund″ site is intended for the production of engineering plastics and TPU. The site would be the third-largest BASF site worldwide, following Ludwigshafen, Germany, and Antwerp, Belgium. The first plant started up in 2022, and the entire site is expected to be completed by 2030.
==== 5.B Transmembrane 1-electron transfer carriers ==== 5.B.1 The Phagocyte (gp91phox) NADPH Oxidase Family 5.B.2 The Eukaryotic Cytochrome b561 (Cytb561) Family 5.B.3 The Geobacter Nanowire Electron Transfer (G-NET) Family 5.B.4 The Plant Photosystem I Supercomplex (PSI) Family 5.B.5 The Extracellular Metal Oxido-Reductase (EMOR) Family 5.B.6 The Transmembrane Epithelial Antigen Protein-3 Ferric Reductase (STEAP) Family 5.B.7 The YedZ (YedZ) Family 5.B.8 The Trans-Outer Membrane Electron Transfer Porin/Cytochrome Complex (ET-PCC) Family 5.B.9 The Porin-Cytochrome c (Cyc2) Family
When Dias was accused for the first time and much time after the beginning of the process, the journalist Hernâni Carvalho critiqued in many points the State's and police work:This only has the bad side of justice. It has the bad side of justice that didn't care about this for anything and it has the shameful side of justice that thirteen years later tries to fix it by hand (...) The Maddie [Madeleine McCann] case had governments, armies, firefighters, everyone looking for the [foreign] kid. This one was Portuguese and no one cared about him (...) We should be ashamed of what is happening. (...) When Rui Pedro went missing no one cared about anything and Afonso Dias, when the kid went missing said in front of many people (...) 'if you want to get the kid back close the borders'. They didn't do anything. And everything they did, was done poorly. (...) If today you know a lot, or a part of what happened it is because (...) the [journalist] Ana Leal did more for this that a lot of police officers that had that obligation. This is a shame. (...) The Portuguese State should already have taken care of this lady [Filomena Teixeira] that's suffering (...) just because they can't give her an answer, they didn't want to give her an answer. (...)
==== Symptomatic treatment ==== Medications used to treat the cognitive symptoms of AD rather than the underlying cause include: four acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine, and donepezil) and memantine, an NMDA receptor antagonist. The acetylcholinesterase inhibitors are intended for those with mild to severe AD, whereas memantine is intended for those with moderate or severe Alzheimer's disease. The benefit from their use is small. Reduction in the activity of the cholinergic neurons is a well-known feature of AD. Acetylcholinesterase inhibitors are employed to reduce the rate at which the body breaks down acetylcholine (ACh), thereby increasing the concentration of ACh in the brain and combating the loss of ACh caused by the death of cholinergic neurons. Evidence supports medical efficacy in mild to moderate AD, and somewhat in the advanced stage. This does not extend to delaying symptom onset. Memantine is a noncompetitive NMDA receptor antagonist first used as an anti-influenza agent. It acts on the glutamatergic system by blocking NMDA receptors and inhibiting their overstimulation by glutamate. Memantine has been reported to have a small benefit in the treatment of moderate to severe AD. The combination of memantine and donepezil has been reported to be "of statistically significant but clinically marginal effectiveness". An extract of Ginkgo biloba known as EGb 761 has been used for treating AD and other neuropsychiatric disorders. Its use is approved throughout Europe.
Sources: en.wikipedia.org
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.
No. Lyophilisation slows degradation rather than stopping it, and the rate depends on residual moisture, temperature and light exposure. Freezer storage extends useful life but does not make the material permanent.
A certificate is only as good as its traceability to a specific batch and a named laboratory. Documents lacking batch numbers, method descriptions or laboratory identifiers carry little weight. Confirming what was actually received generally requires a separate test of the material in hand.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.